WallStreetZenWallStreetZen

NASDAQ: ALVO
Alvotech Stock

$12.00+0.06 (+0.5%)
Updated Jul 22, 2024
ALVO Price
$12.00
Fair Value Price
N/A
Market Cap
$3.20B
52 Week Low
$8.29
52 Week High
$18.00
P/E
-5.77x
P/B
-4.86x
P/S
28.5x
PEG
N/A
Dividend Yield
N/A
Revenue
$114.39M
Earnings
-$494.28M
Gross Margin
-23.9%
Operating Margin
-285.89%
Profit Margin
-432.1%
Debt to Equity
-2.61
Operating Cash Flow
-$244M
Beta
0.13
Next Earnings
Aug 27, 2024
Ex-Dividend
N/A
Next Dividend
N/A

ALVO Overview

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.

Zen Score

Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how ALVO scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

ALVO is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ALVO is unprofitable, so we are unable to assess its PEG ratio
PEG Value Valuation
ALVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
There are 30 more ALVO due diligence checks available for Premium users.

Be the first to know about important ALVO news, forecast changes, insider trades & much more!

Valuation

ALVO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.77x
Industry
-2.34x
Market
29.85x

ALVO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
-4.86x
Industry
2.28x

ALVO's financial health

Profit margin

Revenue
$36.9M
Net Income
-$218.7M
Profit Margin
-592.9%
ALVO's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ALVO's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$1.1B
Liabilities
$1.7B
Debt to equity
-2.61
ALVO's short-term assets ($292.30M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ALVO's long-term liabilities ($1.47B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ALVO's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
ALVO's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$70.8M
Investing
-$3.5M
Financing
$133.2M
ALVO's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

ALVO vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
ALVO$3.20B+0.50%-5.77x-4.86x
HCM$3.52B+6.76%33.70x4.82x
PBH$3.58B+0.63%17.03x2.16x
BHC$2.78B-0.39%-6.15x-2.49x
PRGO$3.78B-0.89%-462.50x0.81x

Alvotech Stock FAQ

What is Alvotech's quote symbol?

(NASDAQ: ALVO) Alvotech trades on the NASDAQ under the ticker symbol ALVO. Alvotech stock quotes can also be displayed as NASDAQ: ALVO.

If you're new to stock investing, here's how to buy Alvotech stock.

What is the 52 week high and low for Alvotech (NASDAQ: ALVO)?

(NASDAQ: ALVO) Alvotech's 52-week high was $18.00, and its 52-week low was $8.29. It is currently -33.33% from its 52-week high and 44.75% from its 52-week low.

How much is Alvotech stock worth today?

(NASDAQ: ALVO) Alvotech currently has 266,821,844 outstanding shares. With Alvotech stock trading at $12.00 per share, the total value of Alvotech stock (market capitalization) is $3.20B.

Alvotech stock was originally listed at a price of $10.40 in Sep 17, 2020. If you had invested in Alvotech stock at $10.40, your return over the last 3 years would have been 15.38%, for an annualized return of 4.89% (not including any dividends or dividend reinvestments).

How much is Alvotech's stock price per share?

(NASDAQ: ALVO) Alvotech stock price per share is $12.00 today (as of Jul 22, 2024).

What is Alvotech's Market Cap?

(NASDAQ: ALVO) Alvotech's market cap is $3.20B, as of Jul 23, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Alvotech's market cap is calculated by multiplying ALVO's current stock price of $12.00 by ALVO's total outstanding shares of 266,821,844.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.